Dr. Ernest found that 82% of her epileptic patients found cannabis treatment helpful, but she also found that many of them were unaware of the doses they were taking or the levels of THC and CBD. Doctors and patients alike need to learn about dosing to maximize their health benefits http://bit.ly/2J29kkB
To explore related information, click the keywords below:
Benjamin Caplan, MDPatients are Unclear on Cannabis Dosing
In overarching trends, one pattern that is seen in the medical literature is a greater tendency for males to be more likely to develop drug abuse disorders than female counterparts, whilst females are more likely to develop anxiety disorders than male counterparts.
Of course, these trends are merely observational patterns in the current literature, which represents a biased perspective of biased subjects, and certainly not etched in stone. Further, many people do not conform to one pre-determined organization system as simple as gender to help educate whether they would be likely to develop drug dependence or anxiety, and even others don’t conform to a single gender. So, a sizeable grain of salt must be taken with what we understand from this literature.
That given, the relevant punch line here is what role might cannabis play in inducing or reducing anxiety across sexes, and how does cannabis might relate to addiction/dependence.
We are still at early stages of these important questions, but one recent study found, that female rats were significantly more likely than male rats to experience anxiety when given large doses of cannabis.
Cannabidiol: a hope to treat non‑motor symptoms of Parkinson’s Disease Patients
Cannabidiol (CBD) has recently been postulated as an ideal drug to address the treatment of non-motor symptoms of Parkinson’s Disease (PD) due to its multifaceted mechanism of action. The plethora of effects of CBD includes anti-inflammatory, neuroprotective, anxiolytic, and antipsychotic actions, which improve non-motor symptoms of PD and lift the quality of life for patients coping with the illness. Further research is recommended to garner support for FDA approval.
A recently published article serves as a call for research to be conducted to discover how cannabis could impact the management of bipolar disorder (BD). Presented in the article is a full review of the advantages and disadvantages of cannabis-based medicine in the treatment of BD and provides insight into possible mechanisms might affect the pathophysiology of the disorder. The insights listed within the article provide the rationale for examining the endocannabinoid system, specifically the cannabinoid receptor 2, with the hopes of finding therapeutic targets for mood control associated with BD.
Anti-histaminic Effects of Resveratrol and Silymarin on Human Gingival Fibroblasts
It has recently been revealed that the flavonoidsresveratrol and silymarin have an anti-histaminic effect on human gingival fibroblasts (HGF). HGF are cells that compose part of the gum tissue in the oral cavity. Silymarin and resveratrol were already known to have anti-bacterial and anti-inflammatory properties, but a recently published study has now revealed that silymarin alone and a combination of the two flavonoids both provide novel therapeutic approaches for inflammation due to allergies.
Some believe that it is difficult to compete with industry giants, such as Tilray and Cronos. But, Israel’s long history of cannabis research and its innovative companies, leading tech and strong agricultural climate make it a likely region to attract many in the global cannabis market. http://bit.ly/2IPXbz8
To explore related information, click the keywords below:
Benjamin Caplan, MDIsrael and the global cannabis market
Tennessee is yet another state looking to regulate hemp effectively, and a proposed solution to this is on-the-go testing kits to determine THC levels in hemp products. If executed well, this could prevent many from being charged with possession of cannabis and save money in the courts and prison systems http://bit.ly/2ISjm7V
To explore related information, click the keywords below:
Benjamin Caplan, MDRegulation of hemp in Tennessee
Title of study: Cannabis use as a risk factor for causing motor vehicle crashes: a prospective study
After legalization in 2018, many Canadian provinces implemented “zero tolerance” policies for drivers who have THC in their systems. But a new study from the University of British Columbia suggests that Canada’s drug-impaired driving laws may be unnecessarily strict. According to researchers, there is no link between THC levels below 5ng/mL and increased risk of car accidents.
Note: Considering the potentially grave risk to life and health for modern culture to make the wrong interpretation of the potential dangers of the effects of cannabis consumption on driving, it is critical for the industry to approach the circumstances with delicacy and diligence. Ideally, everyone involved will be motivated to learn as much as possible about the impact of cannabis on the risks of operating machinery and all will follow a cautious approach which will minimize the risk to all. To that end, it is important to consider and reconcile evidence from multiple perspectives.
Genome-wide association study implicates CHRNA2 in Cannabis Use Disorder
Roughly 9% of cannabis users become dependent. In a recent study, scientists identified a significant association between CHRNA2 gene expression and a diagnosis of Cannabis Use Disorder. In other words, genetics might help to explain why some people may find themselves more dependent upon cannabis than others.
A 2019 literature review summarizes the finding on using THC and CBD on patients with dementia. Researchers found that Dronabinol and THC were associated with significant improvements in a range of psychiatric scores. Interestingly, cannabis products showed the most promising results in patients whose symptoms were previously unmanageable or resistant to other treatments.